Sayuri Cheruvu
Medical Oncology · Mishawaka, INNPI 1134357213
Payments from drug & device makers
Across 82 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$162
- AstraZeneca$147
- Novartis$139
- E.r. Squibb & Sons, L.L.C.$138
- Genentech USA, Inc.$131
- Pfizer$115
- plus $990 from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $162 |
| AstraZeneca | 7 | $147 |
| Novartis | 6 | $139 |
| E.r. Squibb & Sons, L.L.C. | 6 | $138 |
| Genentech USA, Inc. | 6 | $131 |
| Pfizer | 7 | $115 |
| Gilead(2 entities) | 3 | $67 |
| Sobi, Inc | 1 | $62 |
| Merck | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| EMD Serono, Inc. | 2 | $48 |
| Sanofi | 2 | $46 |
| Acrotech Biopharma Inc. | 3 | $43 |
| GSK | 2 | $42 |
| Pharmacosmos Therapeutics Inc. | 2 | $40 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Amgen | 2 | $38 |
| Eisai Inc. | 2 | $38 |
| Tempus AI, Inc | 2 | $37 |
| Pharmaessentia USA Corporation | 2 | $36 |
| Bristol Myers Squibb | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Seagen Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Iovance Biotherapeutics, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Myovant Sciences Inc. | 1 | $14 |
| CTI Biopharma Corp. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $13 |
How this compares
$1,823 in reported general payments places this provider in the 25th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Mishawaka
- Rafat AnsariMishawaka$90K
- Robin ZonMishawaka$12K
- Bilal AnsariMishawaka$9K
- Rashid KhanMishawaka$6K
- Rolan PascualMishawaka$4K
- Jose BufillMishawaka$3K
- Sunil BabuFort Wayne$12.5M
- Bert OneilIndianapolis$7.6M
- Natraj AmmakkanavarIndianapolis$4.1M
- Takefumi KomiyaFort Wayne$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.